A real-world study on the effect of sequential therapy of "dizoltec vaginal gel + Yijunsheng vaginal supposit" on the control of recurrent vaginitis by reconstructing vaginal microecology

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300074352

Enrollment

Unknown

Registered

2023-08-04

Start date

2023-09-01

Completion date

Unknown

Last updated

2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vaginitis

Interventions

Dizoltec vaginal gel + Ejunsun vaginal suppository sequential treatment of vaginitis treatment groups:NA

conventional therapy groups:NA

Eligibility

Sex/Gender

Female

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.18 to 70 years old, female; 2.with bacterial or mould sex vaginitis or mixed vaginitis + bacteria (mold); 3.good follow-up condition, can accept long-term follow-up.

Exclusion criteria

Exclusion criteria: 1.Those who are known to be allergic to the experimental drug or the raw material thereof; 2.pregnant or breastfeeding, or plan to study treatment during pregnancy; 3.asexual life cycle; 4.merging other pathogen infection causes vulvovaginitis (such as trichomonas); 5.a history of history of cervical cancer and cervical intraepithelial neoplasia.

Design outcomes

Primary

Measure	Time frame
Cure rate of vaginitis;The number of recurrent vaginitis;	—

Countries

CHINA

Contacts

Public ContactYanlei Dong

Second Hospital of Shandong University

13515411811@163.com+86 135 1541 1811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026